Logo image
Back
NCI SEER-Linked Virtual Tissue Repository Pilot
Journal article   Open access   Peer reviewed

NCI SEER-Linked Virtual Tissue Repository Pilot

Pamela Sanchez, Alison L Van Dyke, Valentina I Petkov, Yao Yuan, Sarah Bonds, Connor Valenzuela, Alyssa W Tuan, Radim Moravec, Sean F Altekruse, Aatur D Singhi, …
Journal of the National Cancer Institute. Monographs, Vol.2024(65), pp.180-190
08/01/2024
DOI: 10.1093/jncimonographs/lgae034
PMCID: PMC11300006
PMID: 39102878
url
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300006View
Published (Version of record) Open Access

Abstract

Background The Surveillance, Epidemiology, and End Results (SEER) Program with the National Cancer Institute tested whether population-based cancer registries can serve as honest brokers to acquire tissue and data in the SEER-Linked Virtual Tissue Repository (VTR) Pilot. Methods We collected formalin-fixed, paraffin-embedded tissue and clinical data from patients with pancreatic ductal adenocarcinoma (PDAC) and breast cancer (BC) for two studies comparing cancer cases with highly unusual survival (≥5 years for PDAC and ≤30 months for BC) to pair-matched controls with usual survival (≤2 years for PDAC and ≥5 years for BC). Success was defined as the ability for registries to acquire tissue and data on cancer cases with highly unusual outcomes. Results Of 98 PDAC and 103 BC matched cases eligible for tissue collection, sources of attrition for tissue collection were tissue being unavailable, control paired with failed case, second control that was not requested, tumor necrosis ≥20%, and low tumor cellularity. In total, tissue meeting the study criteria was obtained for 70 (71%) PDAC and 74 (72%) BC matched cases. For patients with tissue received, clinical data completeness ranged from 59% for CA-19-9 after treatment to >95% for margin status, whether radiation therapy and chemotherapy were administered, and comorbidities. Conclusions The VTR Pilot demonstrated the feasibility of using SEER cancer registries as honest brokers to provide tissue and clinical data for secondary use in research. Studies using this program should oversample by 45% to 50% to obtain sufficient sample size and targeted population representation and involve subspecialty matter expert pathologists for tissue selection.
 Monograph

Details

Metrics

5 Record Views
Logo image